Faculty:Faculty of Medical Science
Department:School of Medicine
Areas of Expertise: Health, social care and medical innovation
Professor Gordon Wishart is a consultant breast surgeon with expertise in improving patient care, modernising and auditing breast cancer pathways, and translating laboratory research into clinical practice.
Professor Gordon Wishart has been a consultant breast surgeon for 22 years and has had an active breast cancer clinical research programme since his time as a research registrar. He was instrumental in raising £2 million to build the Cambridge Breast Cancer Research Unit in 2008, and was appointed as Visiting Professor of Cancer Surgery at Anglia Ruskin University in December 2008. In 2010 he led a team of clinicians and scientists to produce the Predict model that estimates the survival and treatment benefits following surgery for invasive breast cancer, and he has published widely in the field of breast cancer.
Gordon is a former director of Cambridge Breast Unit (Cambridge University Hospitals NHS Trust, 2005-2010), former deputy director of Cambridge Breast Cancer Research Unit (2008-2010), and current joint lead of Predict breast cancer survival and treatment benefit model management team.
Professor Wishart's main research interests have focused on improving patient care (one-stop clinics, early discharge following breast surgery, nurse-led follow-up clinics), modernisation of breast cancer surgery (introduction of sentinel lymph node biopsy to UK, use of Indocyanine Green for sentinel node biopsy, provision of immediate breast reconstruction), breast cancer survival (survival benefit of screen-detected breast cancer, differences in survival between hospitals, prediction of survival using Predict model) and improvements in breast radiotherapy (development of Cambridge post-mastectomy radiotherapy index, Intensity Modulated radiotherapy, Partial Organ radiotherapy).
“Breast Cancer Related Lymphoedema: methods of investigation of lymphatic drainage and studies into the pathophysiology of the disease”.
“P-glycoprotein expression is significantly associated with increased sestamibi washout in primary hyperparathyroidism”.
“The pathophysiology of lymphoedema”.
Wishart GC, Azzato EM, Pharoah PDP, Greenberg DC, Rashbass R, Kearins O, Lawrence G, Caldas C, Ravdin PM. PREDICT: A new UK prognostic model that predicts survival following surgery for invasive breast cancer. Breast Cancer Res. 2010, Jan 6; 12(1): R1.
Curtis C, Shah SP, Chin S_F, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Graf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S, METABRIC group, Langerod A, Green A, Provenzano E, Wishart G, Pinder S, Watson P, Markowetz F, Murphy L, Ellis I, Purushotham A, Borresen-Dale A-L, Brenton J, Tavare S, Caldas C, Aparicio S. The genomic and transcriptomic architecture of 2000 breast tumours reveals novel subgroups. Nature. 2012; 486(7403): 346-52.
Wishart GC, Loh S-W, Britton PD, Jones L, Benson JR. A feasibility study (ICG-10) of indocyanine green (ICG) fluorescence mapping for sentinel lymph node biopsy in early breast cancer. Eur J Surg Oncol 2012; 38(8): 651-6.
Wishart GC, Bajdik CD, Dicks E, Provenzano E, Schmidt MK, Sherman M, Greenberg DC, Green AR, Gelmon KA, Kosma V-M, Olson JE, Beckmann MW, Winqvist R, Cross SS, Severi G, Huntsman D, Pylkäs K, Ellis I, Nielsen TO, Giles G, Blomqvist C, Fasching PA, Couch FJ, Rakha E, Foulkes WD, Blows FM, Bégin LR, van't Veer LJ, Southey M, Nevanlinna H, Mannermaa A, Cox A, Cheang M, Baglietto L, Caldas C, Garcia-Closas M, Pharoah PDP. PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. Br J Cancer 2012; 107: 800-807.
Mansel RE, MacNeill F, Horgan K, Goyal A, Britten A, Townson J, Clarke D, Newcombe RG, Keshtgar M, Kissin M, Layer G, Hilson A, Ell P, Wishart G, Brown D, West N. Results of a national training programme in sentinel lymph node biopsy for breast cancer. Br J Surg 2013 Apr; 100(5): 654-661.
Benson JR & Wishart GC. Predictors of recurrence for ductal carcinoma in situ following breast conserving surgery. Lancet Oncology August 2013; 14(9): e348-357.
Mukesh MB, Barnett G, Wilkinson JS, Moody AM, Wilson C, Dorling L, Kak CCW, Quian W, Twyman N, Burnet NG, Wishart GC, Coles C. A randomised controlled trial of Intensity Modulated Radiotherapy (IMRT) for early breast cancer: 5-year results confirm superior overall cosmesis. J Clin Oncol 2013; 31(36): 4488-4495.
Earl HM, Vallier AL, Hiller Louise et al. Neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel, with or without gemcitabine, for women with high risk early breast cancer (Neo-tAnGo): an open-label, 2 x 2 factorial randomised phase 3 trial. Lancet Oncol 2014; 15(2): 201-212.
Wishart GC, Axon A. Overcoming the injustices of Gregg v Scott with a new approach to recovering damages in cases of delayed diagnosis of cancer following JD v MELANIE MATHER EWHC 3063 (QB). Clinical Risk 2014; 19(6): 130-138.
Mukesh MB, Qian W, Wilkinson JS, Dorling L, Barnett GC, Moody AM, Wilson C, Twyman N, Burnet NG, Wishart GC, Coles CE. Patient reported outcome measures (PROMs) following forward planned field-in field IMRT: results from the Cambridge breast IMRT trial. Radiother Oncol. 2014; 111(2): 270-275.
Maishman T, Copson E, Stanton L, Gerty S, Dicks E, Durcan L, Wishart GC, Pharoah P, POST Steering Geoup, Eccles D. An evaluation of the prognostic model PREDICT using the POSH cohort of women aged <40 years at breast cancer diagnosis. Br J Cancer 2015; 112: 989-991.
Engelhardt EG, van deb Broek AJ, Linn SC, Wishart GC, Rutgers EJT, van de Velde AO, Smit VTBMH et al. Accuracy of the online prognostication tools PREDICT and Adjuvant! for early stage breast cancer patients younger than 50 years. EJC 2017; 78: 37-44.
Candido dos Reis, Wishart GC, Dicks EM et al. An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation. Breast Cancer Research 2017; DOI 10.1186/s13058-017-0852-3.
Partial breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. The Lancet, August 2017: http://dx.doi.org/10.1016/S0140-6736(17)31145-5.
May 2012: AVMA Annual Clinical Negligence Conference (Keynote Lecture). Cancer & life expectancy.
May 2013: European Society for Surgical Research (ESSR) Annual Congress (Keynote Lecture). Predict: a new online survival and treatment benefit model for early breast cancer.
June 2013: AVMA Annual Clinical Negligence Conference (Keynote Lecture). Proof of causation: a new approach in cancer cases.
November 2016: Russian Oncology Conference (Keynote Lecture). Sentinel node biopsy for early breast cancer.
June 2018: AVMA Annual Clinical Negligence Conference (Opening Keynote Lecture). Lessons learned following criminal prosecution of Birmingham breast surgeon Ian Paterson in 2017.
Regular media invitations from BBC Radio, BBC Look East, National BBC, Sky TV and multiple magazines and publications